Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Trivalent and Quadrivalent Cell-based Virosomal Influenza Vaccines in Healthy Adults
NCT02148328Phase 1Completed
- Sponsor
- Crucell
- Start
- May 2014
- Primary completion
- Oct 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of influenza vaccine (cell-based) in influenza (4 arms), sponsored by Crucell. Primary endpoints: Number of participants with Solicited Local Adverse Events, Number of participants with Solicited Systemic Adverse Events and 2 more. Started May 2014; status: completed.
02
Drugs
influenza vaccine (cell-based)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02148328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148328.